Oxford Vacmedix
Oxford Vacmedix is a privately held, Oxford-based biotechnology company founded in 2012 that develops therapeutic agents for the treatment of cancer, operating with a small (1-10) employee team and most recently funded by a 2018 round led by Cancer Research.
- Company typePrivate
- Founded2012
- HeadquartersOxford, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Oxford Vacmedix does
Oxford Vacmedix is a privately held biotechnology company founded in 2012 and headquartered in Oxford, United Kingdom. Per its stated description, the company develops therapeutic agents for the treatment of cancer, operating in the oncology therapeutics sub-sector with a lean headcount of 1-10 employees consistent with an early-stage or preclinical-stage drug developer. The company originated as a spin-out receiving initial funding from Oxford University Innovation in 2013, and was founded by Shisong Jiang, who continues to serve as Chief Scientific Officer. Operational leadership is provided by CEO William Finch.
The company's core activity is the development of therapeutic agents — a high-risk, capital-intensive endeavor typical of university-sourced oncology biotechs. Its only disclosed material capital event is a $12.5 million funding round in March 2018, led by Cancer Research, which provided meaningful runway to advance the therapeutic pipeline. No commercial products, partnerships, clinical milestones, licensing arrangements, customer agreements, or geographic operations are disclosed in the available data, and the company's website content in the input set does not surface further product, technology, or pipeline detail.
The business model is consistent with a development-stage biotech: capital is raised to fund R&D rather than to support a commercial revenue line, with future monetization typically expected via out-licensing, co-development partnerships, or — at a much later stage — direct commercialization. There is no disclosed pricing model, customer base, revenue, or distribution channel. The company's competitive position rests on intellectual property underlying its therapeutic candidates and on the scientific leadership of its founder, but neither specific patents, pipeline assets, nor clinical trial status are documented in the input data, which limits any deeper moat or valuation assessment.
Oxford Vacmedix firmographics
Firmographics- Name
- Oxford Vacmedix
- Website
- https://oxfordvacmedix.com
- Company type
- Private
- Founded year
- 2012
- Headcount range
- 1–10 employees
- Short description
- Oxford Vacmedix is a privately held, Oxford-based biotechnology company founded in 2012 that develops therapeutic agents for the treatment of cancer, operating with a small (1-10) employee team and most recently funded by a 2018 round led by Cancer Research.
- Ownership category
- akta.pro rank
Oxford Vacmedix industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)
- akta.pro secondary industries
- Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Medical Oncology (HLAKAFAB)
Keywords
Where Oxford Vacmedix is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Oxford Vacmedix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Oxford Vacmedix product offering
Product offeringCore offering
Oxford Vacmedix develops therapeutic agents, specifically cancer vaccines based on recombinant protein technology, for the treatment of cancer. The company focuses on discovery and early-stage development of these oncology therapeutic candidates, leveraging research originating from Oxford University Innovation.
Differentiator
Problem solved
Functional benefit
Products and services
- Therapeutic cancer vaccines Therapeutic agents developed using proprietary recombinant protein technology, intended for the treatment of cancer indications and targeted at pharmaceutical and biotechnology licensing partners.
Companies that use Oxford Vacmedix
Customer profileIdeal customer profiles1 record
Oxford Vacmedix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Oxford Vacmedix partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
Oxford Vacmedix competitors and assessment
Company assessmentDirect peers
- BioNTech: Germany-based biotech developing mRNA-based therapeutic cancer vaccines (e.g., BNT122). Directly comparable as an oncology-focused vaccine developer using a defined antigen-encoding platform to drive tumour-specific T-cell responses.
- Nouscom: European (Basel, Switzerland) clinical-stage biotech developing off-the-shelf and personalised neoantigen cancer vaccines using viral vector and RNA platforms. Closely comparable in stage, modality (therapeutic cancer vaccines), and European footprint.
- Gritstone bio: US-based clinical-stage biotech developing neoantigen-based therapeutic cancer vaccines (GRANITE, SLATE programmes). Comparable in therapeutic focus (tumour-specific T-cell induction) and competitive positioning within the personalised cancer vaccine category.
- CureVac: German mRNA technology company with oncology vaccine programmes (e.g., CV8102). Comparable in modality and as a European-headquartered vaccine-platform biotech, though at a substantially larger scale.
- Transgene: French clinical-stage biotech developing therapeutic vaccines and oncolytic viruses for solid tumours (e.g., TG4001, TG4050). Comparable European peer in the therapeutic cancer vaccine space with similar stage profile.
- Targovax: Norwegian clinical-stage immuno-oncology company developing oncolytic virus and peptide-based cancer vaccines. Comparable modality and European biotech scale; competes for similar oncology-vaccine partnership capital.
- Scancell Holdings: UK-based clinical-stage biotech developing therapeutic cancer vaccines using ImmunoBody and Moditope platforms. Highly comparable as a small UK-listed oncology-vaccine developer with similar size, modality, and European positioning.
Broad incumbents
- Moderna: Major mRNA platform company with a dedicated oncology pipeline (e.g., mRNA-4157 personalised cancer vaccine). Comparable therapeutic modality (cancer vaccines) and adjacent technology class to Oxford Vacmedix's peptide-based vaccine approach.
Emerging players
- VBI Vaccines: Clinical-stage biotech developing virus-like particle (VLP) vaccine platforms with applications in oncology and infectious disease. Comparable as a platform-based vaccine company pursuing therapeutic indications.
- Enterome: France-based clinical-stage biotech developing off-the-shelf and personalised cancer vaccines (EO2401, OncoMimic). Comparable in therapeutic cancer vaccine focus and as a European clinical-stage peer competing for similar partnership opportunities.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
Oxford Vacmedix social profiles
Digital presenceOxford Vacmedix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oxford Vacmedix leadership team
Management profileNumber of profiles
Profiles2 records
Oxford Vacmedix funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oxford Vacmedix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oxford Vacmedix
What does Oxford Vacmedix do?
Oxford Vacmedix develops therapeutic agents, specifically cancer vaccines based on recombinant protein technology, for the treatment of cancer. The company focuses on discovery and early-stage development of these oncology therapeutic candidates, leveraging research originating from Oxford University Innovation.
When was Oxford Vacmedix founded?
Oxford Vacmedix was founded in 2012. It employs 1 to 10 people.
Where is Oxford Vacmedix based?
Oxford Vacmedix is headquartered in Oxford, United Kingdom, in the Europe region.
Who are Oxford Vacmedix's main competitors?
Direct peers on record are BioNTech, Nouscom, Gritstone bio, CureVac, Transgene, Targovax and Scancell Holdings. Moderna is listed as a broad incumbent. Emerging players are VBI Vaccines and Enterome.
Does Oxford Vacmedix have an API?
No public API is recorded for Oxford Vacmedix.
What industry is Oxford Vacmedix in?
Oxford Vacmedix's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection). Its NAICS code is 325414 and its SIC code is 2836.